NYSE - Nasdaq Real Time Price • USD
Emergent BioSolutions Inc. (EBS)
At close: April 25 at 4:00 PM EDT
After hours: April 25 at 7:52 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -0.83 | -0.63 | -2 | 3.67 |
| Low Estimate | -0.83 | -0.63 | -2 | 3.67 |
| High Estimate | -0.83 | -0.63 | -2 | 3.67 |
| Year Ago EPS | -3.17 | -1.06 | -6.23 | -2 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | 224.5M | 244.5M | 1.02B | 1.13B |
| Low Estimate | 224.5M | 244.5M | 1.02B | 1.13B |
| High Estimate | 224.5M | 244.5M | 1.02B | 1.13B |
| Year Ago Sales | -- | 216.17M | 1.05B | 1.02B |
| Sales Growth (year/est) | -- | 13.10% | -2.30% | 9.90% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -1.24 | -0.49 | -0.22 | -0.19 |
| EPS Actual | -3.17 | -1.06 | -0.48 | -0.77 |
| Difference | -1.93 | -0.57 | -0.26 | -0.58 |
| Surprise % | -155.60% | -116.30% | -118.20% | -305.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.83 | -0.63 | -2 | 3.67 |
| 7 Days Ago | -0.83 | -0.63 | -2 | 3.67 |
| 30 Days Ago | -0.83 | -0.63 | -2 | 3.67 |
| 60 Days Ago | -0.22 | -0.34 | 1.54 | 3.67 |
| 90 Days Ago | -0.26 | -0.25 | 1.54 | 1.25 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | EBS | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 73.80% | -- | -- | 2.60% |
| Next Qtr. | 40.60% | -- | -- | 13.40% |
| Current Year | 67.90% | -- | -- | 5.20% |
| Next Year | 283.50% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -25.30% | -- | -- | 11.11% |
| Past 5 Years (per annum) | 34.80% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Benchmark: Buy to Buy | 4/11/2024 |
| Upgrade | Benchmark: Hold to Buy | 3/7/2024 |
| Downgrade | Benchmark: Buy to Hold | 8/29/2023 |
| Reiterates | Benchmark: Buy to Buy | 5/31/2023 |
| Reiterates | Benchmark: Buy to Buy | 5/19/2023 |
| Upgrade | Benchmark: Hold to Buy | 4/10/2023 |
Related Tickers
AMRX Amneal Pharmaceuticals, Inc.
5.90
-2.48%
SIGA SIGA Technologies, Inc.
8.64
-0.23%
EGRX Eagle Pharmaceuticals, Inc.
4.2400
-6.81%
ESPR Esperion Therapeutics, Inc.
1.9900
-6.57%
SBFM Sunshine Biopharma, Inc.
0.8074
-13.18%
DVAX Dynavax Technologies Corporation
11.17
-2.19%
PRGO Perrigo Company plc
31.27
+0.13%
NBIX Neurocrine Biosciences, Inc.
137.76
-0.87%
ELTP Elite Pharmaceuticals, Inc.
0.1295
+2.53%
AQST Aquestive Therapeutics, Inc.
3.9300
+0.77%